Edition:
United Kingdom

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

166.98USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$166.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
98,008
52-wk High
$184.51
52-wk Low
$103.86

Select another date:

Fri, Apr 13 2018

BRIEF-Ligand Pharma Says Co Sent Computershare, As Rights Agent Under Glucagon CVR Agreement

* LIGAND PHARMACEUTICALS SAYS HOLDERS OF GLUCAGON CVRS ENTITLED TO RECEIVE PRO RATA $3.8 MILLION Source text: (https://bit.ly/2JHfcOF) Further company coverage:

BRIEF-Ligand Enters Into Agreement With venBio

* LIGAND ENTERS INTO AGREEMENT WITH VENBIO TO MAKE WORLDWIDE OMNIAB® PLATFORM LICENSE ACCESSIBLE TO PORTFOLIO COMPANIES Source text for Eikon: Further company coverage:

BRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin

* LIGAND PHARMACEUTICALS SAYS ‍ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING​

BRIEF-Ligand Pharma Says‍ Underreported Potential Aggregate Milestone Payments Related To License Agreement With Roivant Sciences

* LIGAND PHARMACEUTICALS SAYS‍ UNDERREPORTED POTENTIAL AGGREGATE MILESTONE PAYMENTS RELATED TO LICENSE AGREEMENT WITH ROIVANT SCIENCES FOR LGD-6972​

BRIEF-Ligand Pharma To Receive Total Potential License & Milestone Payments Of Up To $533.8 Mln, Per Agreement With Roivant

* LIGAND PHARMACEUTICALS - PER TERMS OF LICENSE AGREEMENT WITH ROIVANT, CO TO RECEIVE TOTAL POTENTIAL LICENSE & MILESTONE PAYMENTS OF UP TO $533.8 MILLION

BRIEF-Ligand Pharma Signs License Agreement

* LIGAND PHARMACEUTICALS INC - SIGNED LICENSE AGREEMENT GRANTING ROIVANT SCIENCES EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE LGD-6972 Source text for Eikon: Further company coverage:

BRIEF-Ligand Posts Q4 Adjusted Earnings Per Share $1.31

* LIGAND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Ferring Says Specific Financial Details Of Transaction With Ligand Pharma Are Not Disclosed​

* FERRING ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH LIGAND

BRIEF-Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals

* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH FERRING PHARMACEUTICALS

BRIEF-Ligand Pharma And Glenmark Pharma Enter Into License Agreement

* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS

Select another date: